The latest news from ASCO 2025 focusing on CLL including abstracts, features, and helpful conference information.
Patients with lymphoma or CLL who lacked confidence in their care or doctor were more likely to experience emotional distress and other psychosocial challenges.
A real-world study presented at ASCO 2025 found that patients with CLL/SLL experienced a higher risk of serious infections with one treatment regimen compared to another over 12 and 18 months.
Zanubrutinib plus venetoclax showed promising efficacy and manageable safety in treatment-naïve CLL/SLL, including patients with del(17p) and TP53 mutations.
The 2025 ASCO Annual Meeting showcased new data on therapies for chronic lymphocytic leukemia, including zanubrutinib, acalabrutinib, and liso-cel.
We want to hear from you. Which session are you most looking forward to attending at ASCO?
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
